Interstitial Lung Disease Clinical Trials

If you have idiopathic pulmonary fibrosis (IPF) or any other type of interstitial lung disease (ILD), you may qualify to participate in clinical trials conducted at Cedars-Sinai. By participating in clinical trials, you will have access to the latest medical and surgical techniques, backed by a respected team of specialists and researchers who have helped develop some of the latest treatments for ILD now used around the world.

Questions? See the Clinical Trials FAQs.

Condition:

Idiopathic pulmonary fibrosis

Key Inclusion Criteria

  • ≥40 years old
  • Diagnosed with IPF within four years of screening
  • Diagnosis of IPF is supported by high resolution computed tomography and historical surgical lung biopsy

Summary:

The purpose of this study is to determine the effects of an investigational drug called CC-90001 on patients diagnosed with idiopathic pulmonary fibrosis (IPF), a condition in which scarring of the lungs occurs. Participants will be randomly assigned to receive CC-90001 or placebo (inactive substance). Researchers will assess the effect of CC-90001 on improving IPF, in addition to how well the body tolerates the drug. Another purpose of the study is to determine whether a biomarker test can show how IPF is affected by CC-90001 in a specific group of cells in the body. A biomarker is a biological molecule found in blood, other body fluids, or tissues that may be a sign of a condition or disease.

Condition:

Progressive fibrosing interstitial lung disease

Key Inclusion Criteria

  • At least 18 years old
  • Patients with physician-diagnosed interstitial lung disease (ILD) who fulfill at least one specific criteria for PF-ILD within 24 months of screening visit, despite treatment with unapproved medications used in clinical practice to treat ILD
  • Fibrosing lung disease on high resolution computed tomography

Summary:

This study focuses on patients with progressive fibrosing interstitial lung disease (PF-ILD). The purpose of the study is to evaluate the investigational use of a drug called nintedanib. Researchers aim to determine how well nintedanib may help participants’ lung disease and will compare the safety and effects of nintedanib with placebo (inactive substance). The study involves two parts. The first part will evaluate the effectiveness and safety of nintedanib, and the second part will collect longer-term effectiveness and safety data of the drug.

Condition:

Idiopathic pulmonary fibrosis

Key Inclusion Criteria

  • At least 40 years old
  • Women must be surgically sterile, postmenopausal or agree to use contraception; male subjects must agree to use one or more forms of birth control.
  • Diagnosis of IPF

Summary:

The purpose of this study is to evaluate the investigational use of a drug called BG00011 in patients with idiopathic pulmonary fibrosis (IPF) who are at least 40 years old. The study aims to determine the safety and effectiveness of the drug compared to placebo (inactive substance) in these patients. BG00011 is a laboratory-made antibody that is being developed to treat IPF. An antibody is a type of protein that is made by the body to help protect it from harmful substances. Participants will be randomly assigned to receive either BG00011 or placebo. Researchers also aim to learn whether a biomarker test will help determine the effects of BG00011 on the patient’s IPF. A biomarker is a biological molecule found in blood, other body fluids, or tissues that may be a sign of a condition or disease.